Picture of Nykode Therapeutics ASA logo

NYKD — Nykode Therapeutics ASA News Story

0.000.00%
no flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

Brief: Nykode Therapeutics Announces Positive Final Results From Its Phase 2 Trial Of Vb10.16 In Combination With Pd-L1 Inhibitor Atezolizumab In Advanced Cervical Cancer

April 18 (Reuters) - Nykode Therapeutics ASA  NYKD.OL :
    * NYKODE THERAPEUTICS ANNOUNCES POSITIVE FINAL RESULTS FROM
ITS
PHASE 2 TRIAL OF VB10.16 IN COMBINATION WITH PD-L1 INHIBITOR
ATEZOLIZUMAB IN ADVANCED CERVICAL CANCER
    * NYKODE THERAPEUTICS ASA - VB10.16 WAS SAFE AND WELL
TOLERATED IN
COMBINATION WITH ATEZOLIZUMAB
    * NYKODE THERAPEUTICS- PLANS TO INITIATE POTENTIALLY
REGISTRATIONAL TRIAL IN PD-L1+ PATIENTS WITH HPV16-POSITIVE
ADVANCED CERVICAL CANCER IN U.S. IN 4Q
    * NYKODE THERAPEUTICS:RESULTS SHOWED MEDIAN OVERALL SURVIVAL
GREATER THAN 25 MONTHS, 6.3 MONTHS MEDIAN PROGRESSION FREE
SURVIVAL IN PD-L1+ PATIENTS

Source text for Eikon:  ID:nGNX89nlYw 
Further company coverage:  NYKD.OL 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Nykode Therapeutics ASA

See all news